The Company has a patent portfolio including 49 issued patents in several European countries, USA, Japan, Mexico, Brazil and Chile, and many other patent applications under prosecution in the same countries.

The Company is using its preclinical efficacy and safety results and its strong IP portfolio in seeking to establish a partnership or strategic alliance with a biopharmaceutical company for the co-development, launch and marketing of products for several potential cancer indications.  Some indications may be treated as separate assets with potential for additional partnerships or alliances.